Evidence map›Paper›PMID 39959305›Full record

ArticleNeuro-oncology advances

Transcriptomic analysis of

Santoesha A Ghisai, Nastaran Barin, Levi van Hijfte, Kim Verhagen, Maurice de Wit, Martin J van den Bent, Youri Hoogstrate, Pim J French

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Santoesha A GhisaiDepartment of Neurology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-3289-4294
Nastaran BarinDepartment of Precision and Microsystems Engineering, Delft University of Technology, Delft, The Netherlands.
Levi van HijfteDepartment of Tumor Immunology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
Kim VerhagenDepartment of Neurology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
Maurice de WitDepartment of Neurology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
Martin J van den BentDepartment of Neurology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
Youri HoogstrateDepartment of Neurology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0003-2166-0676
Pim J FrenchDepartment of Neurology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Approximately half of the isocitrate dehydrogenase (IDH)-wildtype glioblastomas (GBMs) exhibit Methods: We used RNA-sequencing (RNA-seq) data to find Results: We identified 2 ligands ( Conclusions:

Indexed as

EGFRglioblastomaligandsRNAtranscriptomics

Identifiers

PMID39959305
PMCPMC11829203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.